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Purpose: The aim of the present study was to develop peptide H9 as an efficient antagonist of human 
cytomegalovirus (HCMV) chemokine receptor US28.  
Methods: US28 gene was amplified from HCMV, and a stable expression system was constructed 
using NIH/3T3 cells. Interaction between peptide H9 and receptor US28 was tested by enzyme-linked 
immunosorbent assay. Flow cytometry was used to determine intracellular concentrations of Ca2+, and 
the possible role of H9 as an antagonist was evaluated by anti-viral experiments.  
Results: H9 interacts with the US28 receptor and prevents an increase of Ca2+ resulting from an 
interaction of chemokine with its receptor. Anti-viral assays showed that H9 could inhibit cytopathic 
effects of HCMV. AD169 infection (EC50 = 0.46 ng/ml), and the production of pp65 antigen were strongly 
inhibited with an EC50 value of 0.34 ng/ml.  
Conclusion: The results demonstrate that H9 is an antagonist of US28, suggesting a possible role as a 
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INTRODUCTION 
 
Human cytomegalovirus (HCMV) is a 
widespread human virus that can infect 
immuno-compromised patients (e.g., HIV-
infected patients, organ transplant recipients 
and newborn babies). Approximately 50 – 80 
% of adults in North America and Europe, 
and approximately 100 % of adults in Asia 
and Africa, test seropositive for HCMV [1, 2]. 
During the last 20 yrs, HCMV infection has 
increased with increase in the numbers of 
immunocompromised individuals [3]. To date, 
no treatment has been developed for HCMV 
infection. 
 
HCMV has developed numerous strategies 
for evading the human immune system. Four 
homologs of host G-protein-coupled 
receptors, including US27, US28, UL33 and 
UL78, are expressed after HCMV infection 
[4]. Among the mimics, US28 is the best 
characterized HCMV-encoded G-protein-
coupled receptor. US28 is thought to act as a 
CC chemokine (CK) sink, to weaken immune 
responses at the infection site. US28 can 
also regulate intercellular transfer of HCMV 
via binding membrane-associated CXCL1 
(fractalkine). Additionally, US28-induced 
vascular smooth muscle cell (SMC) migration 
might play a key role in induction of vascular 
diseases [3]. Therefore, US28 is regarded as 
an attractive target for the development of 
anti-HCMV therapy. 
 
US28 amino acid sequence is approximately 
30% homologous to the mammalian α- and 
β-receptors of leukocytes [5]. Although 
chemokine binding by US28 is different from 
known mammalian β chemokine receptors 
[6], it nonetheless plays an important role in β 
chemokine binding and calcium signaling in 
HCMV infected cells [7]. 
 
To avoid synthesizing a large number of 
peptides, bioinformatic methods were used in 
a previous study to predict the N-terminal 
active site and transmembrane domain of 
US28 [8] and a target synthetic polypeptide 
H22 was selected corresponding to residues 
14-35 near the N-terminal region of US28 
(Phe-Asp-Tyr-Asp-Glu-Asp-Ala-Th-Pro-Cys-
Val-Phe-Thr-Asp-Val-Leu-Asn-Gln-Ser-Lys-
Pro-Val). H22 exhibited no chemotaxic effect 
and could block the binding between 
physiologically active chemokine and 
receptor. Using a random phage library 
including 25 chemokines, 30 positive clones 
were selected. An enzyme-linked 
immunosorbent assay (ELISA) involving 
competitive blocking and competitive 
inhibition was used to identify clone No.5, 
which simulated human macrophage 
inflammatory factor-1β (hMIP-1β) when 
combined with synthetic peptide H22. 
 
The aim of the present study was to design a 
peptide containing 9 amino acids (H9) on the 
basis of the structure of H22, and further 
evaluate its potential as an efficient 




Screening, modification and synthesis of 
peptide H9 
 
A lead peptide was obtained by the phage 
display technique, composed of seven amino 
acids (LNAHCAL). After analysis using 
ProtParam, the target sequence 
VLNAHCALH (H9) was chosen. The 
properties of H9 were as follows: molecular 
weight, 977.1; isoelectric point, 6.88; good 
stability under standard pH and stable 
expression in vitro. The purity was 
determined using high-performance liquid 
chromatography. The molecular weight of H9 
was determined using mass spectrometry. 
 
Construction of cell lines US28-NIH/3T3 
and ORF74-NIH3T3 
 
After infection of strain AD169 (HCMV) for 72 
h, the host cell with virus liquid was boiled for 
10 min, and centrifuged at 12,000 rpm for 5 
min. The supernatant was used for the PCR 
reaction. Primers of US28 were: 5’-
GCCAAGCTTATGACACCGACGACGA-3’ for 
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the upstream primer, and 5’-
TGCTCTAGATTACGGTATAATTTGTGAGA
CG-3’ for the downstream primer. After 
purification, PCR products were digested with 
Xba1 and Hind III restriction enzymes, and 
ligated into plasmid pcDNA3.1. Using calcium 
phosphate, the US28 gene was transferred 
into NIH/3T3 cells. Recombinant clones were 
screened using culture medium containing 
400 µg/ml G-418 disulfide. Cell line ORF74-
NIH/3T3 was constructed in a similar manner. 
DNA was extracted from cell line BCBL 
infected with HHV8. ORF74 gene was 
amplified with the following primers: 5’-
GTGGGATCCGATTACCCTGTTGTTAGCAC
A-3’ for the upstream primer, and 5’-
AGCGTCGACTTATGTCATTTCCTGTGGAG
A-3’ for the downstream primer. The 
expression plasmid was constructed with 
PCR product ORF74 and expression plasmid 
pCEFL, then transfected into NIH3T3 cells. 
 
Binding assay of H9 and receptors 
 
Determination of calcium concentration in 
transfected cells 
 
The concentration of cells was adjusted to 
2×106/ml. Cells were treated as follows: for 
the chemokine group, hMIP-1β (10 ng/ml) 
was used; for the inhibitor group, 100 ng/ml 
H9 was used; for the inhibitor plus chemokine 
group, both hMIP-1β (10 ng/ml) and H9 (100 
ng/ml) were used. After treatment for 24 h, 
cells were washed twice with serum-free 
RPMI1640, and the density of cells was 
adjusted to 1×107/ml. The molecular probe 
Fluo-3/AM was added at the final 
concentration of 10 µM. After incubation in 
the dark for 30 min at 37°C in a 5% CO2 
incubator, cells were washed with ice cold 
phosphate buffered saline (PBS) once, and 
resuspended with 0.5 ml PBS. Samples were 
tested using FACSCalibur flow cytometer 
after filtration. All results were expressed as 
mean ± standard deviation (SD). 
 
Cross-linking of polypeptide H9 with 
receptors ORF74 and US28 
 
Cross-linking of H9 with receptors ORF74 
and US28 was determined using an ELISA 
assay. H9 was diluted to a concentration of 
100 ng/ml, and aliquots (100 µl) were added 
into each well of a 96-well microtiter plate. 
Bovine serum albumin (BSA) and 10 ng/ml 
hMIP-1β were used as negative and positive 
controls, respectively. All assays were done 
in triplicate. After incubation overnight at 4°C, 
unbound polypeptides were removed by 
washing. A PBST solution (200 µl) containing 
2% BSA was added to each well. Following 
incubation at 37°C for 1 h, the plates were 
washed. The cell density of US28-
NIH3T3/ORF74-NIH/3T3 cells were adjusted 
to approximately 1×106/ml, and 100 µl was 
inoculated into each well of the 96-well 
microtiter plate. The pp65 monoclonal 
antibody was diluted with BSA-PBST solution 
at 1:2000, and 50 µl was added to each well. 
Plates were washed after 1 h incubation at 
37°C. Then, the HRP-IgG was diluted with 
BSA-PBST solution at 1:1000, and 100 µl 
was added to each well. Plates were washed 
after 1h incubation at 37°C. 3,3',5,5'-
tetramethylbenzidine chromogenic substrate 
solution (100 µl) was added to each well, 
then incubated at 37°C for 10 min. Stop 
solution (50 µl) was added to each well to 
stop the reaction, and absorbance was read 
at 450 nm. 
 
Anti-HCMV effect of H9 
 
Preparation of strains 
 
Human embryonic lung fibroblast (HELF) 
cells in logarithmic phase were adjusted to a  
concentration of 1×106/ml, and 5-10 µl HCMV 
AD169 virus solution was added to the 
culture. Cytopathicity of cells was observed 
daily using a microscope, and the presence 
of pp65 in the supernatant was monitored 
every 3 days. Cells were tested for virus 
antigen (at approximately 8 days), then 
Liu et al  
Trop J Pharm Res, April 2012;11 (2): 196 
digested, centrifuged, and cryopreserved at -
80°C. 
 
Cytotoxicity detection of H9 
 
Cell toxicity of H9 was determined using the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny 
ltetrazolium bromide) assay. HELF cells in 
logarithmic phase were collected. The 
concentration of the cell suspension was 
adjusted to 5×104/ml, and 200 µl was added 
to wells of a 96-well plate. After incubated at 
37°C in 5% CO2 for 24 h, different 
concentrations of H9 were added to triplicate 
wells. No treatment of the HELF cells was 
used as the control. After 24 h of further 
incubation, an MTT working solution was 
added to each well, followed by a 4 h 
incubation; thereafter, 100 µl dimethyl 
sulfoxide was added to each well and 
incubated for 10 min. The supernatant was 
discarded, and 100 µl dimethyl sulfoxide was 
added to each well and incubated for 10 min. 
The absorbance at 490 nm was measured for 
each well, and the survival rate of cells was 
calculated. 
 
Determination of virus titer after infection 
 
The HCMV virus suspension was diluted by a 
factor of 10x under sterile conditions using 
stock solution. HELF cells in logarithmic 
phase were collected after trypsin digestion, 
and a cell suspension was prepared using 
10% fetal bovine serum in Dulbecco’s 
modified Eagle medium. Cell suspension 
(100 µl) was inoculated into wells of a 96-well 
culture plate, followed by inoculation with a 
dilution series of the virus. Each dilution was 
done in six duplicate wells. The 96-well plate 
was incubated at 37 °C in 5 % CO2 for 7-10 
days. Wells exhibiting the cytopathic effect 
were recorded until there was no longer any 
further development. Infection titer was 
defined as 50% of cells infected (median 
tissue culture infective dose, TCID50). The 
cumulative virus infection titer was obtained 
by the Reed-Muench method [9]. 
 
Inhibition of HCMV- induced cell lesions by 
H9 
 
Serial dilutions of H9 were prepared, and 100 
µl was added in triplicate to wells of a 96-well 
plate. Negative controls included wells with 
cells but no virus, as well as a ganciclovir-
positive control. After adding 80 µl 
suspension containing HELF cells at 
4×105/ml, and 20 µl diluted HCMV 
supernatant, the final volume was 200 µl for 
each well. The 96-well plates were incubated 
at 37°C in 5% CO2 for 5 days, and observed 
for infected cell lesions and counted for the 
number of syncytial cytopathic effects 
(CPEs). CPE inhibitory rate and EC50 (50% 
effective concentration) were calculated 
according to the Reed-Muench method. The 
EC50 value was determined when 50% of the 
infected cells were inhibited by recombinant 
protein. 
 
HCMV replication inhibited by H9 
 
HELF cells infected with HCMV for 2 h, were 
inoculated in triplicate into wells of a 96-well 
plate, then cultured at 37°C in 5% CO2 for 3 
days. The supernatant collected after 
centrifugation was lysed with Triton X-100 
using a volume fraction of 0.005. To detect 
the inhibitory effect of the drug on HCMV 
replication, HCMV-pp65 antigen was 
determined by ELISA. The replication 




The results are presented as mean ±standard 
deviation. The data were analyzed by SPSS 
software version 16. Significant differences (p 
< 0.01) between groups were determined 




Detection and synthesis of H9  
 
The purity of the H9 peptide, determined 
using high-performance liquid chromato-
graphy, was more than 98%. Mass 
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spectrometry was performed to verify the 
sequence of H9. The molecular weight of 
synthetic peptide H9 was calculated as 
977.5, which is consistent with the theoretical 
value. 
 
Expression of receptor ORF74 and US28 
 
PCR analysis of the US28 gene 
demonstrated that digestion with Hind III and 
Xba1 produced several single bands 
successfully (Figure 1), which was necessary 
to the following transfected assay. Western 
blot analysis of US28-NIH/3T3 showed a very 
high intensity band of molecular mass 4.1kDa 
after stained 6h and a low intensity at 
prestained (Figure 2). The results indicated 
the purity of US28-NIH/3T3. Two pictures of 
the ORF74 gene and ORF74-NIH/3T3 have 
been omitted.  
 
Binding of H9 with US28  
 
H9 prevents the elevation of Ca2+ induced by 
hMIP-1β 
 
Figure 3 shows representative results of Ca2+ 
determined by flow cytometry. The data listed 
in Table 1 are the mean ± standard deviation 
of three independent experiments. The 
results showed that 10 ng/ml hMIP-1β can 
significantly increase the Ca2+ (p<0.01). 
Pretreatment with H9 (100 ng/ml) can prevent 
the increase of Ca2+ induced by hMIP-1β. 
 
 
Figure 1: Digestion products of US28 and 
pcDNA3.1. M, molecular weight markers, 15000 
and 2000 marker; 1, digestion products of US28 
digested with Hind III and Xba1 after amplification; 
2, double enzyme digestion products of 
pcDNA3.1-US28; 3, pcDNA3.1 digested with Hind 






Figure 3: Flow cytometry of Ca2+ fluorescence 
Flow cytometry was used for the detection of Ca2+ induced by hMIP-1β, H9 and H9+hMIP-1β respectively. 
The chemokine group (hMIP-1β) can significantly increase the Ca2+, while the chemokine+inhibitor group 
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Figure 2: Western blot analysis of US28-NIH/3T3. 
M, pre-stained protein marker; 1, prestained 
protein; 2, poststained protein after 2 h staining; 3, 
poststained protein after 4 h staining; 4, 
poststained protein after 6 h staining. 
 




hMIP-1β (10ng/ml) 1453±77a 




a p < 0.01 compared with negative control group; b 
p < 0.05 compared with positive control group, 
 
Identification of H9 and US28  
 
The results on Table 2 show that the A450 
value after H9 treatment is much higher than 
the value of the control after BSA treatment 
(p<0.01), indicating that a specific molecular 
interaction existed between H9 and 
US28/ORF74. 
 
Anti-HCMV activity of H9 
 
Cytotoxicity of H9 
 
H9 did not exhibit significant cytotoxicity 
towards HELF cells, with survival rate of each 
treatment group more than 80%. However, 
the positive control involving ganciclovir 
treatment exhibited strong cytotoxicity 





After 8 days of continuous culture, light 
microscopy showed lesions in cells, 
consistent with the replication of intracellular 
virus. No new changes were observed until 
11 days after inoculation. At that time, TCID50 
was calculated when virus amplification was 
no longer increasing. TCID50 was 10
－2.48/100 
µl for HCMV, respectively. 
 
Table 2: ELISA assay of combinations between 
H9 and US28 or ORF74 
 
* p < 0.01 compared with control ; SD = standard 
deviation 
 
H9 inhibition of HCMV-induced cytopathicity 
 
Concentrations of peptide H9 (ranging from  
0.08 - 250 ng/ml) were selected for the 
inhibition assay induced by HCMV. The 
results (not shown) indicate that H9 inhibited 
the formation of CPE in a dose-dependent 
manner. EC50 of H9 (0.46 ng/ml) was greater 
than that of the ganciclovir (GCV) group (0.68 
ng/ml), i.e., positive control group.  
 
H9 inhibits virus replication in HCMV-
infected cells 
 
H9 inhibited production of pp65 in HCMV-
infected HELF cell culture supernatant in a 
dose-dependent manner. The amount of 
pp65 down-regulated by incubating the 
culture supernatants correlated with increase 
in the concentration of H9 or GCV (0.08～250 
ng/ml). The EC50 for H9 was 0.34 ng/ml, 
which was lower than the EC50 for the 




The chemokine receptor is an attractive 
target for drug development, so researchers 
are making great efforts to study antagonists 
of this receptor. To date, there have been a 
variety of chemokine receptor antagonists 
entering phases of animal experiments or 
clinical studies [10-12]. Screening of 
antagonists for their ability to bind to virus-
encoded chemokine receptors is an important 
Mean ± SD (n=3) 
Group Concentra-tion (ng/ml) US28 ORF74 
hMIP-1β 10 0.593±0.085* 0.589±0.072* 
H9 100 0.574±0.023* 0.580±0.041* 
BSA Control 0.108±0.016  0.112±0.014 
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consideration when developing broad 
spectrum anti-viral therapies. 
 
Recently, various small molecules with a 
similar structure to chemokines have been 
used as antagonists to inhibit inflammatory 
responses. These small molecules bind to 
the chemokine receptor, but do not initiate 
cytoplasmic signal transduction cascades. 
Normal physiological functions of chemokine 
receptors can be suppressed by these small 
molecule compounds. The N-terminal region 
of a chemokine is an important candidate site 
for development of antagonists, since it 
initially combines with receptors to start a 
series of signal cascades [13]. Crump et al. 
developed an SDF-1 analog by modifying 
Lys-1 and/or Pro-2 in the N-terminal region of 
SDF-1, using it as a HIV-1 receptor 
antagonist. [13]. 
 
Chemokine receptor US28 constitutes a class 
of receptors, which are similar to multiple 
herpes virus family members such as U12, 
U51 of HHV-7 and HHV-6, and ORF74 of 
HHV-8. Because US28 has the ability to bind 
various chemokines such as CC and CXC, 
this study characterized the binding of US28 
to a broad spectrum of human chemokines. 
On one hand, the US28 receptor can bind to 
a variety of human chemokines. On the other 
hand, a library of broad spectrum chemokine 
peptides can be developed to bind to the CC 
and CXC chemokine classes. In the present 
study, significant differences in absorbance 
were observed between the H9-treatment 
group and negative control BSA-treatment 
group, suggesting a possible interaction 
between “trapping ligand” polypeptide H9 
with the US28 receptor. Furthermore, studies 
of the effect of H9 on intracellular Ca2+ 
concentration show that pretreatment with H9 
could efficiently prevent the elevation of Ca2+ 
concentration induced by hMIP-1β, which 
further demonstrated that H9 was an effective 
antagonist of US28. This result is supported 
by previous findings which showed that CC 
chemokines could increase the intracellular 
concentration of Ca2+ [14]. Given that pp65 is 
highly conserved in various strains of HCMV, 
and detection of pp65 has been considered 
as a standard method for monitoring the 
infection of HCMV [15], the inhibitory 
potential of H9 towards pp65 formation was 
evaluated to estimate the effect of H9 on 
HCMV replication. Our results showed that 
the “trapping ligand” H9 has good anti-viral 
activity, and inhibits replication of HCMV in a 
dose-dependent manner. Because US28 is 
similar to the chemokine receptor of other 
multiple herpes virus family members, H9 
might also exhibit antagonistic effect towards 
these viruses. 
 
An expression system for chemokine 
receptor US28 was successfully constructed 
in vitro. The binding of peptide H9 and US28 
was confirmed, suggesting the signal 
blocking role of H9. In addition, H9 inhibited 
replication of HCMV in vivo. All these results 
indicate that peptide H9 could be a possible 




We characterized the peptide H9, which is an 
efficient antagonist of HCMV chemokine 
receptor US28. At the same time, the anti-
viral test showed that H9 has the potential to 
inhibit the infection of HCMV. These results 
demonstrate that H9 is an antagonist of 
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